Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of α1β12β1 integrins with antiangiogenic activity

Tatjana Momic, Jehoshua Katzehendler, Ofra Benny, Adi Lahiani, Gadi Cohen, Efrat Noy, Hanoch Senderowitz, Johannes A. Eble, Cezary Marcinkiewicz, Philip Lazarovici

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Obtustatin and viperistatin, members of the disintegrin protein family, served as lead compounds for the synthesis of linear and cyclic peptides containing the KTS binding motif. The most active linear peptide, a viperistatin analog, indicated the importance of Cys19 and Cys29, as well as the presence of Arg at position 24 for their biologic activity, and was used as the basic sequence for the synthesis of cyclic peptides. Vimocin (compound 6) and vidapin (compound 10) showed a high potency (IC50 = 0.17 nM) and intermediate efficacy (20 and 40%) in inhibition of adhesion of α12 integrin overexpressor cells to respective collagens. Vimocin was more active in inhibition of the wound healing (53%) and corneal micropocket (17%) vascularization, whereas vidapin was more potent in inhibition of migration in the Matrigel tube formation assay (90%). Both compounds similarly inhibited proliferation (50-90%) of endothelial cells, and angiogenesis induced by vascular endothelial growth factor (80%) and glioma (55%) in the chorioallantoic membrane assay. These peptides were not toxic to endothelial cell cultures and caused no acute toxicity upon intravenous injection in mice, and were stable for 10-30 hours in human serum. The in vitro and in vivo potency of the peptides are consistent with conformational ensembles and "bioactive" space shared by obtustatin and viperistatin. These findings suggest that vimocin and vidapin can serve as dual α 1β12β1 integrin antagonists in antiangiogenesis and cancer therapy.

Original languageEnglish
Pages (from-to)506-519
Number of pages14
JournalJournal of Pharmacology and Experimental Therapeutics
Issue number3
StatePublished - Sep 2014

Bibliographical note

Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.


Dive into the research topics of 'Vimocin and vidapin, cyclic KTS peptides, are dual antagonists of α1β12β1 integrins with antiangiogenic activity'. Together they form a unique fingerprint.

Cite this